Journal of Gerontological Nursing

Product News Free

Product News

U.S. Food and Drug Administration Approves Bedding to Reduce Occurrence of Pressure Ulcers

DermaTherapy® bedding technology was specifically developed to create a new generation of health care bedding that reduces the overall occurrence of pressure ulcers. Its silk-like fibers help regulate patients' “microclimate”—a combination of heat, moisture, pressure, friction, and shear. Conventional hospital bedding often generates excessive moisture, friction, and shear while generating lint and airborne particles—all potentially hazardous to patients.

DermaTherapy has already been used extensively in clinical trials throughout the country and the results are highly encouraging. One large Midwestern university medical center saved $1.5 million and reduced patients' length of stay, due in large part to a reduction of hospital-acquired pressure ulcers. Standard Textile is working to introduce its product to as many hospitals and care facilities as possible. The recent U.S. Food and Drug Administration clearance will add momentum to this effort.

Source.“FDA-Cleared Bed Linens Engineered to Reduce Development of Pressure Ulcers.” (2016, September 19). Retrieved November 2, 2016, from http://prn.to/2ff1MuU.

Patients Enrolled in Study of Piromelatine for Alzheimer's Disease

Neurim Pharmaceuticals announced that the first patients have been enrolled in the ReCOGNITION study of its novel drug, piromelatine, for Alzheimer's disease (AD).

ReCOGNITION is a Phase 2, randomized, placebo-controlled, dose-ranging study of piromelatine (5, 20, and 50 mg daily) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety, and tolerability in patients with mild dementia due to AD. The 26-week trial will compare once-daily oral doses of piromelatine to placebo in approximately 500 patients with mild AD and treated with stable doses of acetylcholinesterase inhibitors.

ReCOGNITION was designed following pre-clinical studies with piromelatine demonstrating neuroprotection and neurogenesis potential. In a previous Phase 2 study, piromelatine demonstrated improvements in sleep maintenance and, specifically, enhanced deep, slow-wave, sleep.

Source.“Neurim Pharmaceuticals Announces First Patients' Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimer's Disease.” (2016, September 28). Retrieved November 2, 2016, from http://prn.to/2eorYnn.

Authors

10.3928/00989134-20161110-02

Sign up to receive

Journal E-contents